生产企业：Cocrystal Pharma, Inc.
First oral direct-acting antiviral in development for the prevention and treatment of norovirus infection; Cocrystal Pharma's lead candidate, granted FDA Fast Track designation.
First oral direct-acting antiviral in development for the prevention and treatment of norovirus infection; Cocrystal Pharma's lead candidate, granted FDA Fast Track designation.
Oral, direct-acting 3CL protease inhibitor designed to target the highly conserved region of the 3CL protease across all known norovirus strains (including GII.4 and the re-emerging GII.17 variants) as well as all coronaviruses.
Treatment and prophylaxis of norovirus infection
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
